Abstract Background Coronavirus disease 2019 (COVID-19) continues to pose a significant
threat to public health worldwide. The purpose of this study was to review current evidence …

Background: We provided a comprehensive evaluation of efficacy of available treatments for
coronavirus disease 2019 (COVID-19). Methods: We searched for candidate COVID-19 …

Objectives This study aimed to evaluate the efficacy and adverse events of favipiravir in
patients with COVID-19. Methods Our protocol was registered on PROSPERO …

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is a new coronavirus in
the Coronaviridae family. The COVID-19 pandemic, caused by SARS-CoV-2, has …

Objectives There are limited data on the efficacy and safety of favipiravir antiviral in
coronavirus disease 2019 (COVID-19), particularly in the more progressed disease phase …

Since December 2019, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
infection has exploded and led to a global crisis. Currently, the global case numbers topped …

Introduction Several randomized controlled trials have compared the effectiveness of
favipiravir with that of placebo. However, evidence regarding its effect on nonsevere, early …

On 30 January 2020, the World Health Organization (WHO) declared the novel severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic a public health emergency of …

Background This meta-analysis of randomized controlled trials (RCTs) investigated the
clinical efficacy and safety of favipiravir for patients with mild-to-critical COVID-19. Methods …

Since the early days of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
pandemic, therapeutic trials into pharmacological management of coronavirus-2019 (COVID …